WO2019133752A1 - Procédé de prédiction de l'efficacité d'un médicament - Google Patents

Procédé de prédiction de l'efficacité d'un médicament Download PDF

Info

Publication number
WO2019133752A1
WO2019133752A1 PCT/US2018/067746 US2018067746W WO2019133752A1 WO 2019133752 A1 WO2019133752 A1 WO 2019133752A1 US 2018067746 W US2018067746 W US 2018067746W WO 2019133752 A1 WO2019133752 A1 WO 2019133752A1
Authority
WO
WIPO (PCT)
Prior art keywords
kras
mutations
gene
csf
drug
Prior art date
Application number
PCT/US2018/067746
Other languages
English (en)
Inventor
Jia-Ming Chang
Yi-Ru Lee
Chiung-Wen Liou
Hsiang-Ping Huang
Yuan-Jen Huang
Original Assignee
Development Center For Biotechnology
Dcb-Usa Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Development Center For Biotechnology, Dcb-Usa Llc filed Critical Development Center For Biotechnology
Publication of WO2019133752A1 publication Critical patent/WO2019133752A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the present invention relates generally to methods for predicting drug efficacies or effects.
  • Companion diagnosis may be used to determine whether the drug would he beneficial to the patient based on their biological characteristics (e.g., genetic profiles) that determine responders and non-responders to the therapy.
  • Companion diagnosis detects and assess biomarkers that can prospectively help predict likely outcome of the therapy (e.g., efficacies and toxicities).
  • companion diagnosis can also be used to monitor drug responses during treatment. This information may help doctors find new treatment strategies.
  • Companion diagnosis is relatively new and only a handful of drugs have established companion diagnosis. For example, companion diagnosis assessing the Her2 expression levels is helpful in deciding whether to use Herceptin for breast cancer treatment.
  • EGFR inhibitors can often shrink lung cancer. However, cancer cells eventually become resistant to the drug due to T970M mutation in the EGFR gene. Companion diagnosis of this mutation can help doctors switch the drugs to newer EGFR inhibitors that can work against ceils with the T790M mutation, such as osimertinib (Tagrisso®).
  • companion diagnosis has been shown to be helpful in selecting proper treatments for patients, there are only few established companion diagnoses at the moment.
  • Embodiments of the invention relate to diagnostic techniques for predicting therapeutic efficacy.
  • a method for predicting therapeutic efficacy of a drug in accordance with one embodiment of the invention includes analyzing a panel of genes to derive information for predicting whether a patient will respond to the drug.
  • the analyzing a panel of genes includes analysis of gene mutations, copy number variations, and/or expression levels.
  • the panel of genes comprises PIK3CA, KRAS, PTEN, BRAF, and CSF-1R.
  • the gene mutations may include E542K, E545K, and H1047R mutations in PIK3CA, G12C, G12D, G12V, G13D mutations in KRAS, R130G and C71F/Y mutations or deletion in PTEN, V600E mutation in BRAF, and H362R mutation in CSF-1R.
  • the drug may be a colony stimulating factor 1 receptor (CSF-1R) inhibitor.
  • CSF-1R inhibitor may be a small molecule drug, a biologic, or a nucleotide.
  • the nucleotide may be siRNA or miRNA.
  • the drug may be a drug targeting a protein translated from a gene in the panel of genes.
  • the drug may be a phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) inhibitor, a KRAS (also known as K-ras or Ki-ras) inhibitor, a phosphatase and tensin homolog (PTEN) inhibitor, or a BRAF (also known as B-Raf) inhibitor.
  • PIK3CA catalytic subunit alpha
  • KRAS also known as K-ras or Ki-ras
  • PTEN phosphatase and tensin homolog
  • BRAF also known as B-Raf
  • the analyzing makes use of multiplexing illumine, real-time polymerase chain reaction (PCR), next-generation sequencing (NGS), gene chips, microfluidics, flowcytometry, or a combination thereof.
  • PCR real-time polymerase chain reaction
  • NGS next-generation sequencing
  • the analyzing a panel of genes may be performed simultaneously in a multiplex format.
  • a method in accordance with one embodiment of the invention comprises using magnetic beads coupled with a probe to react with a sample to detect presence or absence of a target gene, wherein the probe can hybridize with a fragment of the target gene.
  • the target gene is KRAS and the probe is designed to detect G12D mutation in KRAS.
  • the probe is coupled with biotin for interaction with streptavidin-R-phycoerythrin to permit multiplexing illumine detection for fluorescence intensity and quantity.
  • the probe has the sequence of 5’-
  • FIG. 1 shows a schematic illustrating various factors involved in CSF-1R signaling. Based on analysis of gene databases from various cancer cells, it was found that PIK3CA and KRAS have high mutation rates in breast cancer and colorectal cancer. The incidence rates for PIK3CA mutations in various cancers are shown, as well as incidence rates for KRAS mutations in various cancers.
  • FIG. 2 shows a schematic illustrating various factors involved in CSF-1R signaling. Based on analysis of gene databases from various cancer cells, it was found that PTEN and BRAF have high mutation rates in glioma and thyroid cancer. The incidence rates for PTEN mutations in various cancers are shown, as well as incidence rates for BRAF mutations in various cancers.
  • FIG. 3 shows results from cross analyses of PIK3CA, KRAS, PTEN, and BRAF mutations. The results from these analyses revealed that among the colorectal cancers and thyroid cancers, the rates of having two or more mutations impacting these gene functions are as high as 40% among all different races.
  • FIG. 4 shows the results from hybridization between magnetic beads that are coupled with a probe and a target KRAS G12D sequence.
  • FIG. 5 shows results from probe specificity tests.
  • a Kras WT probe (0.2 nmol) is allowed to hybridize with either the wild-type Kras or a mutant Kras GAT (mGl2D). The results show that the probe of the invention is specific.
  • FIG. 6A shows results from testing optimal hybridization temperatures at 0.2 pmol of wild-type and mutant Kras. Magnetic beads with wild type Kras probe are hybridized with either the wild-type Kras or a mutant Kras GAT (mGl2D) sequence at different temperature and the median fluorescence intensity (MFI) values are measured to assess the hybridization. The results show that the hybridization proceed better and produce more stable results at higher temperatures, e.g., 60-80 °C.
  • FIG. 6B shows results from testing optimal hybridization temperatures at 0.05 pmol of wild-type and mutant Kras.
  • FIG. 6C shows results from testing optimal hybridization temperatures at 0.005 pmol of wild-type and mutant Kras.
  • Magnetic beads with a mutant Kras Mt probe are hybridized with a mutant Kras target sequence for different hybridization times and the median fluorescence intensity (MFI) values are measured to assess the hybridization.
  • MFI median fluorescence intensity
  • FIG. 7B shows results from testing for optimal hybridization times. Magnetic beads with a mutant Kras Mt probe are hybridized with a wild-type Kras target sequence for different hybridization times and the median fluorescence intensity (MFI) values are measured to assess the hybridization. The results show that a hybridization time of about 10 minutes proceed better and produce more stable results.
  • MFI median fluorescence intensity
  • Embodiments of the invention relate to diagnostic techniques for predicting therapeutic efficacy. Methods of the invention can be used as companion diagnosis to screen patients for subpopulations that would respond to a particular therapy, thereby increasing the probability of therapeutic success and avoiding waste of medical resources.
  • a method for predicting therapeutic efficacy of a drug may include the step of analyzing a panel of genes to derive information for predicting whether a patient will respond to the drug.
  • the analyzing a panel of genes may include analysis of gene mutations, copy number variations, and/or expression levels.
  • CSF-1R inhibitor therapy will be described.
  • the companion diagnosis may include analysis of genes that are involved in the CSF-1R signaling pathways.
  • genes for example, may include PIK3CA, KRAS, PTEN, and BRAF.
  • CSF-1R inhibition has been used to target tumor-associated macrophages in cancer therapy.
  • CSF-1R inhibition treatments vary among patients of different races, suggesting that different genetic backgrounds may play an important role.
  • PIK3CA, KRAS, PTEN, and BRAF mutations of genes immediately downstream from CSF-1R in the signaling pathways, such PIK3CA, KRAS, PTEN, and BRAF, may have impacts on the efficacy of CSF- 1R inhibitor therapy.
  • Mutations of these genes are frequently associated with various cancers.
  • several potential mutations including E542K, E545K, and H1047R mutations in PIK3CA, G12C, G12D, G12V, G13D mutations in KRAS, R130G and C71F/Y mutations or deletion in PTEN, V600E mutation in BRAF, and H362R mutation in CSF-1R, are found that might have impacts on CSF-1R inhibitor therapy.
  • CSF1 colony stimulating factor- 1
  • CSFIRV colony stimulating factor- 1 receptor
  • CSFIRV colony stimulating factor- 1 receptor
  • CSF-1R inhibition has been used to target tumor-associated macrophages in cancer therapy.
  • the effects of CSF-1R inhibition treatments seem to vary among patients of different races, suggesting that genetic backgrounds may play an important role. Therefore, analyzing genes and mutations related to CSF-1R signaling pathways may provide information to help predict therapy outcomes.
  • the cancer gene databases used for such analysis may include GENIE (AACR
  • cBioPortal platform (v.1.8.3) (http://www.cbioportal.org/index.do).
  • cBioPortal for Cancer Genomics is a tool developed at Memorial Sloan Kettering Cancer Center’s Computational Biology Center (cBio).
  • CSF-1R signal transduction related genes include CSF1R, PIK3CA, PTEN, KRAS, and BRAF.
  • the mutation rates of these genes were analyzed with respect to various cancers (glioma, oral cancer, thyroid cancer, lung cancer, breast cancer, stomach cancer, liver cancer, biliary tract cancer, colorectal cancer, ovary cancer, and uterus endometrial cancer) in patients of different races.
  • PIK3CA and KRAS have more than 5% mutation rates among all cancers.
  • the mutation rate of PIK3CA is about 31.3% in breast cancer, and the mutation rate for KRAS in non-small cell adenocarcinoma is about 27%.
  • the mutations of PIK3CA and KRAS are accompanied by increases in the CSF-1R activity. These mutations are also related to the lack of responses to treatments in the clinics.
  • PTEN and BRAF are the actors that interact directly with PIK3CA and KRAS, respectively. Therefore, mutations that affect PTEN (e.g., R130G, C71F/Y, and deletions) and BRAF (V600E) functions are expected to have a negative impact on the effects of CSF-1R inhibitors. Analyzing the potential impacts of these mutations on cancer treatments, it was found that these may affect up to 9% glioma patients among Caucasians and up to 50% thyroid cancers patients among Caucasians and Asians. (FIG. 2). Thus, these mutation analyses may be used to predict the percentages of patients that may not respond to the CSF-1R inhibitor treatments.
  • PTEN e.g., R130G, C71F/Y, and deletions
  • V600E V600E
  • CSF-1R signaling pathways play roles in CSF-1R inhibition treatments. These factors include CSF-1R, PIK3CA, PTEN, KRAS, and BRAF. Analyzing functional mutations that affect the functions of these factors may provide information to predict which patients would benefits from CSF-1R inhibition treatments and which patients would not.
  • Example 2 Use of cell lines to establish methods for analyzing gene mutations
  • genomic DNAs were obtained from lung cancer cells A549, H727, HCC-827, H1975, NCI-H146, H460, and H292.
  • gene fragments for CSF-1R, PIK3CA, KRAS, and PTEN were obtained using polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • the sequences of these gene fragments were determined using Sanger’s sequencing methods, and then the sequences were compared with the sequences of the same fragments from normal cells. The comparison would reveal any nucleotide differences. The mutation locations were further confirmed.
  • the procedures for sequence determination and analysis are as follows:
  • Genomic DNA extraction was performed using DNeasy Blood & Tissue Kit
  • the target lung cancer cells were collected in centrifuge tubes. The cells were washed with lx PBS to remove DMSO used to preserve cells in the frozen aliquots. The tubes were centrifuged, and the top clear solutions were discarded. To the cell pellets in the tubes were added 180m1 ATL lysis buffer (Qiagen) and 20m1 proteinase K. Mix and resuspend the cell pellets. Place the tubes in an oven at 56°C for 4 hours to digest proteins. After protein digestion, add 200m1 AL lysis buffer to the tubes and mix well. Then, add 200m1 pure ethanol and mix well.
  • TERTARA Polymerase
  • DNA sequencing was performed using Sanger’s method. Sequence analysis of the PCR products were performed using BigDye Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA). Each reaction uses 50 ng primers and l pl BigDye mixture, 10 ng PCR product, and I m ⁇ 5x reaction buffer. PCR was performed in GeneAmp PCR System 2700 thermocycler (Applied Biosystems, Foster City, CA). The reaction conditions are: 96°C initial denaturation for 1 minute, 96°C denaturation for 10 seconds, 50°C annealing for 10 seconds, repeat for 45 cycles, and then extend at 60°C for 4 minutes.
  • Biosystems which can sequence to 700-800 bps on average. Compare the sequences of CSF- 1R, PIK3CA, KRAS and PTEN from lung cancers cells with those from normal cells to determine the differences. Then, confirm the mutation locations.
  • H727, HCC-827, H1975, NCI-H146, H460, and H292 have been analyzed. Mutations in CSF-1R, PIK3CA, KRAS, and PTEN are found (FIG. 1 and FIG. 2). Results from these analyses shows that most genes are wild-type genes. Genes from lung cancer cells A549 and H727 have mutations at G12 (Table 2). These mutations can be accurately determined.
  • HCC-827, and H1975 mutations observed for CSF-1R, PIK3CA, KRAS and PTEN.
  • the results show that most genes are wild-type, and only KRAS from A549 and H727 have mutations at G12 location, PI3K from HCC-827 and H1975 have mutations at E545.
  • This example describes gene detection and analysis methods based on Luminex xMAP (Multi-Analyte Profiling; Luminex Corp., Austin, TX), gene-probe design, and hybridization techniques.
  • gene probes for the target DNA sequences e.g., CSF-1R, PIK3CA, KRAS, BRAF, and PTEN
  • the gene probes are used to detect specific target genes as follows. Select the gene probes that are specific for the target genes. Couple the selected gene probes on specific magnetic beads. Mix fluorescent magnetic beads for different assay samples. Add the amplified fragments of the assay samples and detect them with fluorescence labeled probes on the magnetic beads. Then, use flow cytometry to detect the types of magnetic beads and measure the fluorescence intensities.
  • This method can provide multiple genes detection and can achieve fast and accurate detection.
  • the methods can be used in the clinics.
  • KRAS mutations are often associated with colorectal cancer, pancreatic cancer, lung cancer, etc.
  • the most frequent KRAS mutations are found at positions G12 and G13.
  • the mutations at G12 are more common than those at G13, making the G12 mutations more relevant in the therapeutic responses.
  • An object of the invention is to provide methods for detecting G12 mutations in
  • Embodiments of the invention are based on the Liminex xMAP (Multi- Analyte Profiling) principle and make use of magnetic bead probes to detect gene mutations.
  • a method of the invention may include the steps of: expansion of the test sample, gene-probe design, and hybridization reactions. Briefly, a gene probe is coupled on magnetic beads and then added to the test sample that has been expanded (e.g., using PCR). The probe or beads may contain fluorescent tags, which would allow one to differentiate different magnetic beads using flow cytometry. The different magnetic beads permit differentiation of mutant or wild-type genes. In addition, the fluorescence intensities may be used to quantify the species. These methods allow one to perform gene diagnosis with speed and accuracy, as well as quantitation. [0053] An exemplary method will be described for illustration. However, one skilled in the art would appreciate that this example is for illustration only and that other modifications and variations are possible without departing from the scope of the invention.
  • the primers for Kras gene detection can be derived from the Kras sequence in the literature with some modifications.
  • a biotin can be attached to the 5’ end of the reverse primer, as shown in Table 4.
  • a wild-type (Wt) probe and a Kras G12D (GAT) mutant-type (Mt) probe may be designed, as shown in Table 5.
  • Wt wild-type
  • GAT Kras G12D
  • Mt mutant-type
  • DNA extracts are prepared from human cell lines or patient-derived xenograft
  • PDX samples Use specific modified primers and PCR to expand specific Kras gene fragments and tag them with fluorescence markers.
  • Beads with different codes are mixed well in 0.1M 2-
  • Kras G12D (GAT) mutant-type (Mt), are synthesized. The 5’ ends of these sequences are tagged with biotin. The two sequence fragments are 59 b.p. long, which serve as the standards for constructing the analysis platform.
  • the hybridization reactions are conducted in 96-well PCR plates. Each well is loaded with 2500 beads, which are mixed with the above-described synthetic sequences. The total volume per well is 50 ul.
  • the hybridization is performed in a PCR machine (Biometra Tadvanced). After hybridization, the samples in the PCR plate are transferred into a 96-well dark plate. With the aid of a magnetic plate, the upper layer clear solutions are discarded. Streptavidin-R-phycoerythrin (75 ul/well) was added to each well, and the binding reaction was allowed to proceed at room temperature for 30 minutes. The median fluorescence intensity (MFI) of the magnetic beads was measured using a Magpix equipment (Luminex).
  • MFI median fluorescence intensity
  • Kras G12D Mt probe are hybridized with different concentrations (0.005, 0.025, 0.05, 0.1, and 0.2 pmol) of the Kras G12D Mt sequence. The hybridization was performed at 95 °C for 5 minutes and then at 52°C for 30minutes. As shown in FIG. 4, Kras G12D Mt probe can detect Kras G12D Mt sequence in the range of 0.025-0.1 pmol, with a lowest detection limit of 0.025 pmol.
  • Wt probe are hybridized with different concentrations (0.005, 0.025, 0.05, 0.1, and 0.2 pmol) of the Kras Wt and Kras G12D Mt sequences. The hybridization was performed at 95 °C for 5 minutes and then at 52°C for 30minutes. As shown in FIG. 5, Kras Wt probe can hybridize with the Kras Wt sequence with a higher affinity than with the Kras G12D Mt sequence. Thus, the magnetic probes are specific.
  • Kras Wt probe are separately hybridized with low, medium, and high concentrations (0.005, 0.05, and 0.2 pmol) of the Kras Wt and Kras G12D Mt sequences, respectively.
  • the hybridization was performed at 95°C for 5 minutes and then at 23.3 - 75°C for 30minutes.
  • the MFI values show that Kras Wt probe can form more stable hybrids with both the Kras Wt and Kras G12D Mt sequences, as compared with at low hybridization temperatures. Therefore, a preferred hybridization temperature for a detection platform of the invention would use a relatively high hybridization temperature, such as 65-80°C, more preferably around 70°C (e.g., 70.6°C).
  • the Wt probe are separately hybridized with low, medium, and high concentrations (0.005, 0.05, and 0.2 pmol) of the Kras Wt and Kras G12D Mt sequences, respectively.
  • the hybridization was performed at 95°C for 5 minutes and then at 70.6°C to observe hybridizations at different reaction times (1, 5, 10, 15, 20, and 30minutes).
  • FIG. 7A and FIG. 7B with a hybridization time of 10 minutes, Kras G12D Mt probe at medium and high concentrations (0.05 and 0.2 pmol) can hybridize with Kras Wt and Kras G12D Mt sequences to produce the best MFI values, as compared with other hybridization time.
  • the hybridization time is preferably selected for 10 minutes for the detection platform of the invention.
  • the accuracy of the detection platform can be tested as follows. Human cell lines and patient-derived xenograph (PDX) samples are expanded with PCR to obtain the target gene fragments. Then, using the Quick Microbeads Kras Gene Detection Platform to detect the gene states. The detection samples have been analyzed and their gene sequences determined. Therefore, they can be used as the standards for assessing the detecting platform. Then, the samples are analyzed in 10 blind tests, each time with 10 PCR products and each sample is tested in quadruples. From these tests, it was found the detection platform or methods of the invention have an accuracy of 99% after testing 100 PCR products. Thus, a detection platform/method of the invention has the advantages of system stability and detection accuracy.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de prédiction de l'efficacité thérapeutique d'un médicament comprenant l'analyse d'un panel de gènes pour déduire des informations pour prédire si un patient répondra au médicament. L'analyse d'un panel de gènes comprend l'analyse de mutations génétiques, de variations de nombre de copies et/ou de niveaux d'expression. Le panel de gènes comprend PIK3CA, KRAS, PTEN, BRAF et CSF-1R Les mutations géniques comprennent les mutations E542K, E545K et H1047R dans PIK3CA, les mutations G12C, G12D, G12V, G13D dans KRAS, les mutations ou délétions R130G et C71F/Y dans PTEN, la mutation V600E dans BRAF et la mutation H362R dans CSF-1R. Le médicament est un inhibiteur de CSF-IR.
PCT/US2018/067746 2017-12-28 2018-12-27 Procédé de prédiction de l'efficacité d'un médicament WO2019133752A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762611529P 2017-12-28 2017-12-28
US62/611,529 2017-12-28

Publications (1)

Publication Number Publication Date
WO2019133752A1 true WO2019133752A1 (fr) 2019-07-04

Family

ID=67068185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/067746 WO2019133752A1 (fr) 2017-12-28 2018-12-27 Procédé de prédiction de l'efficacité d'un médicament

Country Status (2)

Country Link
TW (1) TW201938795A (fr)
WO (1) WO2019133752A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116463353A (zh) * 2022-12-23 2023-07-21 首都医科大学附属北京天坛医院 Csf1r基因突变小鼠模型构建方法及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110008347A1 (en) * 2006-12-01 2011-01-13 Agency For Science ,Technology And Research Cancer-related protein kinases
US20110269124A1 (en) * 2009-08-11 2011-11-03 Response Genetics Methods, Primers, Probes and Kits Useful for the Detection of BRAF Mutations
WO2013113748A1 (fr) * 2012-02-02 2013-08-08 Primer Design Ltd Procédé pour détecter et génotyper un acide nucléique cible
US20130224740A1 (en) * 2010-09-03 2013-08-29 Centre National De La Recherche Scientifique(Cnrs) Analytical methods for cell free nucleic acids and applications
US20140186844A1 (en) * 2011-04-26 2014-07-03 Swift Biosciences, Inc. Polynucleotide primers and probes
US20150057275A1 (en) * 2009-04-24 2015-02-26 The General Hospital Corporation Methods and materials for genetic analysis of tumors
US20150152510A1 (en) * 2011-01-11 2015-06-04 Roche Molecular Systems, Inc. High resolution melting analysis as a prescreening tool
US20150307947A1 (en) * 2012-12-04 2015-10-29 Caris Mpi, Inc. Molecular profiling for cancer
US20170051361A1 (en) * 2014-05-09 2017-02-23 Memorial Sloan-Kettering Cancer Center Biomarkers for response to pi3k inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110008347A1 (en) * 2006-12-01 2011-01-13 Agency For Science ,Technology And Research Cancer-related protein kinases
US20150057275A1 (en) * 2009-04-24 2015-02-26 The General Hospital Corporation Methods and materials for genetic analysis of tumors
US20110269124A1 (en) * 2009-08-11 2011-11-03 Response Genetics Methods, Primers, Probes and Kits Useful for the Detection of BRAF Mutations
US20130224740A1 (en) * 2010-09-03 2013-08-29 Centre National De La Recherche Scientifique(Cnrs) Analytical methods for cell free nucleic acids and applications
US20150152510A1 (en) * 2011-01-11 2015-06-04 Roche Molecular Systems, Inc. High resolution melting analysis as a prescreening tool
US20140186844A1 (en) * 2011-04-26 2014-07-03 Swift Biosciences, Inc. Polynucleotide primers and probes
WO2013113748A1 (fr) * 2012-02-02 2013-08-08 Primer Design Ltd Procédé pour détecter et génotyper un acide nucléique cible
US20150307947A1 (en) * 2012-12-04 2015-10-29 Caris Mpi, Inc. Molecular profiling for cancer
US20170051361A1 (en) * 2014-05-09 2017-02-23 Memorial Sloan-Kettering Cancer Center Biomarkers for response to pi3k inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAN ET AL.: "Functional Evaluation of PTEN Missense Mutations Using in Vitro Phosphoinositide Phosphatase Assay1", CANCER RESEARCH, vol. 60, 15 June 2000 (2000-06-15), pages 3147 - 3151, XP055623341 *
KANAGAL-SHAMANNA ET AL.: "Next-Generation Sequencing-Based Multi- Gene Mutation Profiling of Solid Tumors Using Fine Needle Aspiration Samples: Promises and Challenges for Routine Clinical Diagnostics", MODERN PATHOLOGY, vol. 27, no. 2, 2 August 2013 (2013-08-02), pages 1 - 14, XP055623343 *
SCHWAEDERLE ET AL.: "Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next Generation Sequencing", CANCER RESEARCH, vol. 77, no. 19, 14 August 2017 (2017-08-14), pages 5419 - 5427, XP055623346 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116463353A (zh) * 2022-12-23 2023-07-21 首都医科大学附属北京天坛医院 Csf1r基因突变小鼠模型构建方法及其应用
CN116463353B (zh) * 2022-12-23 2023-09-19 首都医科大学附属北京天坛医院 Csf1r基因突变小鼠模型构建方法及其应用

Also Published As

Publication number Publication date
TW201938795A (zh) 2019-10-01

Similar Documents

Publication Publication Date Title
WO2017112738A1 (fr) Procédés pour mesurer l'instabilité microsatellitaire
CA3026809A1 (fr) Compositions et procedes de diagnostic de cancers du poumon a l'aide de profils d'expression genique
US20170247765A1 (en) Methods for rapid and sensitive detection of hotspot mutations
JP2024020392A (ja) 特定の遺伝子のｃｐｇメチル化変化を利用した肝癌診断用組成物およびその使用
EP3927849A1 (fr) Panel de biomarqueurs pour le diagnostic et le pronostic du cancer
WO2019133752A1 (fr) Procédé de prédiction de l'efficacité d'un médicament
US20180223367A1 (en) Assays, methods and compositions for diagnosing cancer
US20190360061A1 (en) Methods and kits for identifying pre-cancerous colorectal polyps and colorectal cancer
CN113999901B (zh) 心肌特异性甲基化标记物
WO2018123764A1 (fr) Réactif mis en œuvre pour l'évaluation de maladie résiduelle minimale de neuroblastome, et procédé d'analyse d'échantillon biologique à l'aide de celui-ci
CN107090508B (zh) 一种检测基因突变的新型试剂盒
US20230054587A1 (en) Multiplexed Assay Using Differential Fragment Size to Identify Cancer Specific Cell-Free DNA
CN104531866B (zh) 用于结肠直肠癌中使用的生物标志物
JP2016189746A (ja) プライマー対、プローブ、薬剤耐性ｃ型肝炎ウイルスの検出キット、薬剤耐性ｃ型肝炎ウイルスの検出方法およびｃ型肝炎の予後予測方法
CN113166810A (zh) 包括gba基因单碱基多态性的脑动脉瘤诊断用snp标志物
JP7299765B2 (ja) マイクロｒｎａ測定方法およびキット
US20230358749A1 (en) Early cancer diagnosis method and diagnostic kit using interferon gamma gene concentration measurement in exosomes
WO2024048753A1 (fr) Procédé, polynucléotide et kit pour évaluer le risque d'apparition d'un cancer de l'estomac chez un patient après élimination d'helicobacter pylori
WO2022157764A1 (fr) Dépistage non invasif du cancer sur la base de changements de méthylation de l'adn
WO2014182726A2 (fr) Marqueurs génétiques utilisables en vue du traitement de la dégénérescence maculaire
EP4186006A1 (fr) Cadre d'apprentissage profond pour identifier des mutations somatiques non codantes pathogènes à partir de génomes de cancer personnels
CN115125302A (zh) miRNA在制备乳腺癌耐药性评估的诊断试剂或试剂盒中的应用
TW201335375A (zh) 提升檢測ｋｒａｓ編碼子１２及１３突變之靈敏度及專一性之方法
KR20180032062A (ko) 항암제 저항성 또는 민감성 예측용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18894050

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18894050

Country of ref document: EP

Kind code of ref document: A1